Ownership and insider activity for Crinetics Pharmaceuticals, Inc. (CRNX): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist.
Price
| Price | $84.95 |
| Market Cap | $9.0B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-01 | WIERENGA WENDELL | D-Return | 116,146 | $9.9M |
| 2026-09-01 | WIERENGA WENDELL | D-Return | 5,925 | $504K |
| 2026-09-01 | WIERENGA WENDELL | D-Return | 12,500 | $290K |
| 2026-09-01 | WIERENGA WENDELL | D-Return | 12,500 | $290K |
| 2026-09-01 | WIERENGA WENDELL | D-Return | 17,500 | $354K |
| 2026-09-01 | WIERENGA WENDELL | D-Return | 17,500 | $320K |
| 2026-09-01 | WIERENGA WENDELL | D-Return | 17,500 | $356K |
| 2026-09-01 | WIERENGA WENDELL | D-Return | 12,500 | $559K |
| 2026-09-01 | WIERENGA WENDELL | D-Return | 10,350 | $335K |
| 2026-09-01 | WIERENGA WENDELL | D-Return | 9,730 | $349K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $12.2M | $14.2M | $45.0M | $40.3M | $93.1M | $200.7M | $32.7M | $54.9M | $264.5M | $101.5M |
| Short-term Investments | 0 | 0 | $118.9M | $78.1M | $77.8M | $133.0M | $301.8M | $503.7M | $1.09B | $926.4M |
| Receivables | $72000 | $734000 | 0 | $1.4M | $1.8M | $2.0M | $2.4M | $9.4M | $8.5M | $592000 |
| Inventory | $98000 | $141000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $2.0M |
| Total Current Assets | $12.4M | $15.2M | $166.7M | $123.3M | $177.5M | $344.7M | $345.2M | $574.2M | $1.38B | $1.05B |
| Property, Plant & Equipment | $224000 | $400000 | $4.2M | $6.5M | $5.4M | $4.7M | $5.0M | $57.4M | $55.6M | $54.8M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $12.6M | $15.6M | $171.4M | $130.4M | $183.4M | $351.0M | $352.2M | $635.4M | $1.43B | $1.14B |
| Accounts Payable | $340000 | $403000 | $1.5M | $2.7M | $3.5M | $4.3M | $6.9M | $6.5M | $5.9M | $22.6M |
| Short-term Debt | $49000 | 0 | 0 | $724000 | 0 | $939000 | $1.1M | $4.2M | 0 | $6.5M |
| Total Current Liabilities | $890000 | $897000 | $7.9M | $8.3M | $10.5M | $16.0M | $27.7M | $43.9M | $59.7M | $85.1M |
| Long-term Debt | $163000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $18.8M | $30.6M | $11.2M | $13.2M | $14.5M | $19.1M | $35.8M | $96.2M | $109.8M | $143.4M |
| Retained Earnings | -$7.1M | -$16.3M | -$43.4M | -$93.8M | -$167.6M | -$275.3M | -$439.2M | -$653.7M | -$952.1M | -$1.42B |
| Total Equity | -$6.2M | -$15.0M | -$43.4M | $117.1M | $168.9M | $331.9M | $316.3M | $539.1M | $1.32B | $992.1M |
| Total Debt | $212000 | 0 | 0 | $5.6M | $4.0M | $4.0M | $3.1M | $51.7M | $51.7M | $48.5M |
| Net Debt | -$11.9M | -$14.2M | -$163.9M | -$112.8M | -$166.9M | -$329.7M | -$331.4M | -$506.8M | -$1.30B | -$979.3M |
| Working Capital | $11.5M | $14.3M | $158.8M | $115.0M | $167.0M | $328.7M | $317.5M | $530.2M | $1.32B | $963.3M |
Financial Health
| Debt / Equity | 0.04 |
| Current Ratio | 15.57 |
| Piotroski F-Score | 2 |
| Altman Z-Score | 16.09 |
Profitability
| Return on Equity | -44.22% |
| Return on Invested Capital | -43.98% |
| Return on Assets | -37.95% |
| Gross Margin | 99.16% |
| Operating Margin | -1302.52% |
| Net Margin | -1189.88% |
Related companies: ACAD · AKRO · DYN · IMVT · KYMR · NAMS · PRAX
Explore sector: Healthcare · Biotechnology
More sections of CRNX: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks